Inclusion Criteria:

- Multiple myeloma confirmed by bone marrow aspirate or biopsy

- Patient had to have relapsed and/or refractory multiple myeloma after at least 1
standard therapy, and have demonstrated disease progression

- Previous exposure to Velcade was allowed, provided no DLTs of Grade 3 or above had
been observed during previous treatment (for Part 2 of the study only)

Exclusion Criteria:

- Prior therapy with any IGF-1 system targeting compound

- History of allogenic stem cell transplantation in case of concomitant
immunosuppressive therapy within 6 months before study entry. Patients having
undergone autologous stem cell transplantation(s) may have been included in the study

- History of organ transplant and any patient receiving long term systemic
immunosuppressive therapy

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.